Zacks: BiomX Inc. (NASDAQ:PHGE) Receives Consensus Rating of “Strong Buy” from Analysts

BiomX Inc. (NASDAQ:PHGE) has received an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Analysts have set a 1 year consensus price target of $28.00 for the company, according to Zacks. Zacks has also assigned BiomX an industry rank of 143 out of 255 based on the ratings given to related companies.

Shares of NASDAQ:PHGE traded up $0.21 during midday trading on Friday, reaching $9.25. The company had a trading volume of 1,718 shares, compared to its average volume of 21,488. BiomX has a one year low of $6.13 and a one year high of $11.90.

In other BiomX news, Director Erez Chimovits acquired 5,400 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was purchased at an average price of $8.92 per share, with a total value of $48,168.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Israel Biofund Gp Limi Orbimed acquired 3,400 shares of the firm’s stock in a transaction on Thursday, December 5th. The stock was acquired at an average cost of $7.99 per share, with a total value of $27,166.00. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 21,400 shares of company stock valued at $181,754.

BiomX Company Profile

BiomX Ltd discovers and develops microbiome-based therapeutics to prevent and treat cancer and inflammatory bowel disease (IBD). It uses its 3-tier microbiome modulation platform and applies it to identify target bacteria causing microbiome dysbiosis; modulates the microbiome through adding or eradicating bacteria; and engages in pre-clinical/clinical drug development.

See Also: Why is momentum important to successful trading?

Get a free copy of the Zacks research report on BiomX (PHGE)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with's FREE daily email newsletter.